<DOC>
	<DOCNO>NCT01842035</DOCNO>
	<brief_summary>The purpose study determine whether blunted heart rate response regadenoson independent predictor sudden cardiac death .</brief_summary>
	<brief_title>Heart Rate Response Regadenoson Sudden Cardiac Death</brief_title>
	<detailed_description>In patient heart failure history sudden cardiac death , Implantable Cardiac Defibrillator ( ICD ) reduce death rate . However , patient ICD receive appropriate therapy . Inappropriate ICD shock common associate bad quality life increase death rate . We hope establish good predictor risk sudden cardiac death response ICD . We conduct prospective observational study 150 patient ( 18-80 year ) indication ICD implantation primary prevention sudden cardiac death . Prior implantation clinically indicate ICD , heart rate response regadenoson assess . Regadenoson administer intravenously fix intravenous bolus dose 400 Î¼g follow 5 mL saline flush . The main objective proposal investigate whether : 1 . A blunted heart rate response regadenoson independent predictor sudden cardiac death . 2 . A blunted heart rate response regadenoson use predictor response ICD top traditionally used indicator . We Hypothesize : 1 . Patients blunt heart rate response regadenoson high risk sudden cardiac death ( death appropriate cardiac defibrillation ) . This risk maintain control age , gender , leave ventricular ejection fraction , heart failure symptom medication use . 2 . Patients normal heart rate response regadenoson low rate event ( death appropriate cardiac defibrillation ) despite meet current indication ICD .</detailed_description>
	<mesh_term>Death</mesh_term>
	<mesh_term>Death , Sudden , Cardiac</mesh_term>
	<mesh_term>Ventricular Dysfunction , Left</mesh_term>
	<mesh_term>Regadenoson</mesh_term>
	<criteria>Inclusion criterion : Age 1980 year Female subject must ( ) least one year postmenopause surgically sterile ( b ) nonpregnant ( c ) nonlactating . Subject must able willing provide write informed consent Subject must refer clinically indicated ICD fall one follow group : subject leave ventricular ejection fraction le 35 % due prior myocardial infarction least 40 day postmyocardial infarction NYHA functional Class II III . subject nonischemic dilate cardiomyopathy leave ventricular ejection fraction less equal 35 % NYHA functional Class II III . Subjects leave ventricular dysfunction due prior myocardial infarction least 40 day postmyocardial infarction , leave ventricular ejection fraction le 30 % , NYHA functional Class I . Female subject pregnant lactating Subject active severe asthma chronic obstructive pulmonary disease , Investigator 's opinion , place subject risk severe bronchoconstriction Treatment dipyridamole , theophylline , aminophylline pentoxifylline within 24 hour receive regadenoson Treatment investigational drug within 30 day 5 half life whichever longer prior study entry Subject prior allergic response aminophylline contraindication receive intravenous regadenoson Subjects second third degree atrioventricular block dependent pacemaker Subject uncontrolled severe hypertension ( systolic &gt; 200 mmHg diastolic &gt; 120 mmHg ) pretreatment hypotension ( systolic BP &lt; 90 mmHg ) Subject hemodynamically significant aortic stenosis outflow tract obstruction Subject decompensated heart failure ( NYHA functional class IV ) Subject acute myocardial infarction , new onset ischemia , percutaneous coronary intervention , coronary artery bypass graft within 30 day receive regadenoson Subject dialysis end stage renal disease estimate glomerular filtration rate &lt; 15 mL/min Subjects cardiac transplantation</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Implantable cardiac defibrillator</keyword>
	<keyword>regadenoson</keyword>
	<keyword>sudden cardiac death</keyword>
	<keyword>heart rate response</keyword>
</DOC>